Search Results
Your search for Matthew Stenger matches 7752 pages
Showing 5001 - 5050Understanding of Stage and Cancer Status Among Patients in a Community-Based Cancer Institute
As reported by Sivendran et al in the Journal of Oncology Practice, half of patients in a large community-based cancer institute did not know their stage of cancer, and one-third did not know of their cancer-free/in-remission status. Study Details The study involved 208 adult patients treated at...
Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma
The phase I CheckMate 016 trial has shown activity of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in metastatic renal cell carcinoma. These findings were reported in the Journal of Clinical Oncology by Hammers et al. Study Details In the dose-escalation study, patients were...
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Metastatic Brain Disease
In the phase III NCCTG N107C/CEC.3 trial, stereotactic radiosurgery to the surgical cavity reduced cognitive deterioration and was associated with similar overall survival vs whole-brain radiotherapy in patients with resected brain metastasis. These results were reported by Brown et al in The...
Prophylactic Cranial Irradiation vs Observation in Extensive-Disease Small Cell Lung Cancer
A Japanese phase III trial has shown no survival benefit of prophylactic cranial irradiation vs observation in patients with extensive-disease small cell lung cancer who had any response to platinum-based doublet chemotherapy and no brain metastases at baseline. These findings were reported in The...
Avelumab in Refractory Metastatic Urothelial Carcinoma
The programmed cell death ligand 1 (PD-L1)–inhibitor avelumab (Bavencio) has shown activity in patients with refractory metastatic urothelial cancer, according to findings in a phase Ib study reported by Andrea B. Apolo, MD, of the Genitourinary Malignancies Branch, Center for Cancer Research,...
No Survival Benefit When Pravastatin Is Added to Standard Chemotherapy in Small Cell Lung Cancer
In a UK phase III study (LUNGSTAR) reported in the Journal of Clinical -Oncology, Michael J. Seckl, MD, PhD, of Imperial College London, and colleagues found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer...
Insertion and Deletion Mutations and Immunogenicity in Solid Tumors
In a study reported in The Lancet Oncology, Turajlic et al found that renal cell carcinomas were characterized by the highest proportion and number of frameshift insertion and deletion (indel) mutations among solid cancers and that these alterations were associated with augmented immunogenicity...
Effect of Methotrexate and Corticosteroid Strategies on Neurocognitive Function in Patients With B-Lineage ALL
In a Children’s Oncology Group (COG) study (AALL06N1) reported in the Journal of Clinical Oncology, Hardy et al found that age < 10 years at diagnosis was associated with poorer neurocognitive function in patients with high-risk B-lineage acute lymphoblastic leukemia regardless of...
MammaPrint Scoring and Indolent Node-Negative Breast Cancer
In an analysis reported in JAMA Oncology, Esserman et al found that an ultralow-risk designation using the 70-gene MammaPrint assay is capable of identifying patients with node-negative disease who have a very low long-term risk of death from breast cancer after surgery without systemic therapy....
Nivolumab Treatment Beyond Disease Progression in Advanced Melanoma
In a retrospective analysis reported in JAMA Oncology, Long et al found that a substantial proportion of patients with advanced melanoma derived benefit from continued nivolumab (Opdivo) treatment after Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1–defined disease...
CD33 Splicing Polymorphism and Response to Gemtuzumab Ozogamicin in AML
In an analysis of the phase III Children’s Oncology Group AAML0531 trial, published by Lambda et al in the Journal of Clinical Oncology, the CD33-targeted immunoconjugate gemtuzumab ozogamicin was shown to have benefit among patients with de novo acute myeloid leukemia (AML) who carry the CC...
Anthracycline-Free Adjuvant Treatment in Early TOP2A-Normal Breast Cancer
The Danish phase III DBCG 07-READ trial has shown no difference in disease-free survival with adjuvant docetaxel/cyclophosphamide vs epirubicin, cyclophosphamide, and docetaxel in patients with early TOP2A-normal breast cancer. These trial results were reported in the Journal of Clinical Oncology...
Factors Associated With Near-Miss/Safety Incidents in Cancer Radiotherapy
In a single-institution case-control analysis reported in the Journal of Oncology Practice, Judy et al found that complexity of procedure or schedule was a significant factor in near-miss or safety incidents involving cancer patients undergoing radiotherapy. Study Details The study involved a...
Overall Survival With Nivolumab vs Chemotherapy in Ipilimumab-Refractory Advanced Melanoma
As reported in the Journal of Clinical Oncology by Larkin et al, the phase III CheckMate 037 trial has shown no difference in overall survival with nivolumab (Opdivo) vs investigator’s choice of chemotherapy in ipilimumab (Yervoy)-refractory advanced melanoma. More chemotherapy patients never ...
Effect of Patient-Reported Symptoms on Adherence to Preventive Treatment for Breast Cancer
In an analysis of the UK cohort of the International Breast Cancer Intervention Study (IBIS-I) reported in the Journal of Clinical Oncology, Smith et al found similar effects of predefined symptoms on nonadherence in both tamoxifen and placebo recipients. IBIS-I randomized women at high risk of...
Idarubicin vs High-Dose Daunorubicin Induction in Newly Diagnosed Acute Myeloid Leukemia
A Korean phase III trial has shown no difference in outcomes with high-dose daunorubicin vs idarubicin induction in newly diagnosed acute myeloid leukemia, although high-dose daunorubicin was associated with better outcomes in patients with FLT3–internal tandem duplication (ITD) mutation....
Adding Evofosfamide to Doxorubicin in Advanced Soft-Tissue Sarcoma
A phase III trial (TH CR-406/SARC021) has shown no survival benefit of adding evofosfamide to doxorubicin in the first-line treatment of locally advanced unresectable or metastatic soft-tissue sarcoma. Trial results were reported in The Lancet Oncology by Tap et al. Evofosfamide is a...
Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Patients With Resected Pancreatic Cancer
IN THE EUROPEAN phase III ESPAC-4 trial reported in The Lancet, John P. Neoptolemos, MD, of the Liverpool Clinical and Cancer Research UK Trials Unit, University of Liverpool, and colleagues found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients...
Pembrolizumab Is Highly Active in Relapsed/Refractory Classical Hodgkin Lymphoma
AS REPORTED in the Journal of Clinical Oncology by Robert Chen, MD, of City of Hope National Medical Center, and colleagues, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) is highly active in patients with relapsed/...
No Efficacy Difference Between Adjuvant Letrozole and Anastrozole in Postmenopausal Women With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Ian E. Smith, MD, of The Royal Marsden Hospital and Institute of Cancer Research, and colleagues, final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in...
Blinatumomab in B-Precursor Acute Lymphoblastic Leukemia
In a phase II trial reported in the Journal of Clinical Oncology, Giovanni Martinelli, MD, of S. Orsola University Hospital, Bologna, and colleagues found that blinatumomab (Blincyto) produced complete responses in patients with relapsed/refractory Philadelphia chromosome–positive B-precursor...
Final Results of European Trial in Mucosa-Associated Lymphoid Tissue Lymphoma
The final results of the European phase III International Extranodal Lymphoma Study Group (IELSG)-19 trial, reported in the Journal of Clinical Oncology by Emanuele Zucca, MD, of the IELSG Operation Office, Oncology Institute of Southern Switzerland, and colleagues showed that event-free and...
Effect of Salvage Surgery on Survival in Recurrence After Treatment of Rectal Cancer
In a large single-center analysis reported in the Journal of Clinical Oncology, Ikoma et al found that salvage surgery was associated with prolonged survival in patients with lung-only and liver-only recurrence but not in those with locoregional-only recurrence after preoperative chemotherapy and...
MET Inhibitor Savolitinib in Advanced Papillary Renal Cell Cancer
In a biomarker-based phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that the MET tyrosine kinase inhibitor savolitinib was active in MET-driven advanced papillary renal cell cancer. Study Details In the trial, 109 patients with locally advanced or metastatic...
Adding Sorafenib to Transarterial Chemoembolization in Hepatocellular Carcinoma
As reported in The Lancet Gastroenterology & Hepatology by Meyer et al, the UK phase III TACE 2 trial has shown no progression-free survival benefit with the addition of sorafenib (Nexavar) to transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. The trial was...
Mutations in Myelodysplastic Syndrome Associated With Poorer Outcome After Stem Cell Transplantation
In a study reported in The New England Journal of Medicine, R. Coleman Lindsley, MD, PhD, of Dana-Farber Cancer Institute, and colleagues found that a number of mutations present in patients with myelodysplastic syndromes (MDS) were associated with poorer clinical outcome after allogeneic...
Two Studies Show Scalp Cooling Reduces Hair Loss in Women Receiving Chemotherapy for Breast Cancer
An interim analysis of the SCALP trial, reported in JAMA by Julie Nangia, MD, of Baylor College of Medicine, and colleagues, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling.1 The ...
Adding Idelalisib to Bendamustine/Rituximab in Relapsed/Refractory CLL
As reported by Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet Oncology, interim analysis of a phase III trial has shown the superiority of adding the phosphoinositide-3-kinase δ inhibitor idelalisib (Zydelig) to bendamustine/rituximab (Rituxan) in...
Interventionist-Guided Weight Loss Program for African American Breast Cancer Survivors
As reported by Stolley et al in the Journal of Clinical Oncology, a community-based interventionist-guided weight loss program for African American breast cancer survivors (Moving Forward) proved successful in achieving weight loss goals compared with a self-guided weight loss program. African...
Adding Midostaurin to Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation
In a phase III trial (Cancer and Leukemia Group B 10603 [RATIFY]/Alliance) reported in The New England Journal of Medicine, Stone et al found that the addition of midostaurin (Rydapt) to standard chemotherapy improved overall survival in patients with newly diagnosed acute myeloid leukemia with...
First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Advanced Colorectal Cancer
A phase III trial has shown no significant difference in overall survival with first-line cetuximab (Erbitux) vs bevacizumab (Avastin) plus chemotherapy in patients with advanced or metastatic KRAS wild-type colorectal cancer. These study findings were reported by Venook et al in JAMA. The trial...
Study Estimates Risks of Breast and Ovarian Cancers in BRCA1/2-Mutation Carriers
In a prospective cohort study reported in JAMA, Kuchenbaecker et al derived estimates of cumulative risks for breast, ovarian, and contralateral breast cancers among women carrying BRCA1 or BRCA2 mutations. Study Details The study involved data from 6,036 BRCA1 and 3,820 BRCA2 carriers recruited...
Outcome by Age With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in the Journal of Clinical Oncology by Brose et al, a prespecified analysis of the phase III double-blind SELECT trial of lenvatinib (Lenvima) vs placebo in radioiodine-refractory differentiated thyroid cancer showed progression-free survival benefits in both older and younger...
First-Line Nivolumab vs Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 5%
As reported by Carbone et al in The New England Journal of Medicine, the phase III CheckMate 026 trial has shown no progression-free survival benefit for first-line nivolumab (Opdivo) vs platinum-based chemotherapy in patients with recurrent or stage IV non–small cell lung cancer with...
Dabrafenib Plus Trametinib in BRAF V600–Mutant Melanoma Brain Metastases
A phase II trial has shown that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinst) produces responses in brain metastases in patients with BRAF V600–mutant melanoma. These findings were reported by Davies et al in The Lancet Oncology. Study ...
Brentuximab Vedotin vs Physician’s Choice in CD30-Positive Cutaneous T-Cell Lymphoma
The phase III ALCANZA trial has shown that brentuximab vedotin (Adcetris) produces a higher global response rate vs physician’s choice of therapy in previously treated CD30-positive cutaneous T-cell lymphomas. These results were reported by Prince et al in The Lancet. Study Details In this...
Impact of Palliative Care on End-of-Life Services for Patients Dying in a Hospital
In a single-center retrospective analysis reported in the Journal of Oncology Practice, Wiesenthal et al found that among patients dying in a hospital, those with palliative care in place at final admission received less diagnostic testing and other services not associated with promoting patient...
Atezolizumab as First-Line or Subsequent Treatment in PD-L1–Selected Advanced NSCLC
In the phase II BIRCH trial, atezolizumab (Tecentriq) was found to produce higher response rates as first-line or subsequent therapy in patients with advanced non–small cell lung cancer (NSCLC) with higher levels of programmed cell death ligand 1 (PD-L1) expression. Study findings were...
Lu-177 Dotatate Improves Progression-Free Survival in Advanced Progressive Midgut Neuroendocrine Tumors
In the phase III NETTER-1 trial reported in The New England Journal of Medicine, Jonathan R. Strosberg, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues found that the addition of the targeted radiotherapeutic agent lutetium Lu-177 dotatate to the long-acting repeatable (LAR)...
ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers in Colorectal Cancer
As reported in the Journal of Clinical Oncology by Antonia R. Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...
Effect of Postdiagnosis Aspirin and Other NSAIDs on Survival in Colorectal Cancer
As reported by Hua et al in the Journal of Clinical Oncology, long-term survivors of colorectal cancer with KRAS wild-type tumors had improved survival with regular use of any nonsteroidal anti-inflammatory drug (NSAID) post diagnosis. The study involved data from 2,149 patients aged 18 to 74...
Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Adjuvant Therapy for Breast Cancer
The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by...
Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma
In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. John P....
Testosterone Replacement Therapy and the Risk of Prostate Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Stacy Loeb, MD, of New York University, and colleagues found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among...
Decreasing but Still Elevated Risk for Subsequent Neoplasms in Survivors of Childhood Cancer
In a retrospective multicenter cohort study reported in JAMA, Lucie M. Turcotte, MD, MPH, of the University of Minnesota, Minneapolis, and colleagues found that the risk of subsequent neoplasms in 5-year survivors of childhood cancers decreased between those diagnosed in the 1970s vs the 1990s but ...
Equivalence Trial of Neoadjuvant Trastuzumab Biosimilar CT-P6 vs Trastuzumab in HER2-Positive Breast Cancer
A phase III equivalence trial has shown comparable pathologic complete response rates with the proposed trastuzumab biosimilar CT-P6 vs reference trastuzumab (Herceptin) in neoadjuvant treatment of HER2-positive early breast cancer. The study was reported by Stebbing et al in The Lancet Oncology....
Effect of Embedding Palliative Care in an Oncology Clinic
A retrospective analysis reported in the Journal of Oncology Practice by Einstein et al showed the benefits of embedding palliative care in a clinic specializing in targeted and immune-based treatments in patients with melanoma or renal cancer. Study Details The study included data from 114...
Trends in Surgery After Initial Lumpectomy for Breast Cancer
In a study reported in JAMA Oncology, Morrow et al found that the rates of surgery after initial lumpectomy for stage I or II breast cancer have decreased with dissemination of guidelines advocating a minimal negative surgical margin. A 2014 consensus statement of the Society of Surgical Oncology...
Impact of Subsidies on Use of Oral Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma
According to a study by Olszewski and colleagues in the Journal of Clinical Oncology, Medicare Part D beneficiaries without a low-income subsidy may face daunting barriers in affording oral immunomodulatory drugs for myeloma. The low-income subsidy markedly reduces out-of-pocket costs for...
Ceritinib vs Chemotherapy in Previously Treated ALK-Rearranged NSCLC
The phase III ASCEND-5 trial has shown a significant improvement in progression-free survival with ceritinib (Zykadia) vs chemotherapy in advanced ALK-rearranged non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori) and chemotherapy. Trial results were reported in...
